Beauty Product Marketing Claims Deconstructed

www.drmanishshah.com

Image

We are all subject to marketing and advertising on a daily basis. Nowadays it seems like even thinking about skin care will get you bombarded with countless ads and sponsored post on social media. But how trustworthy are some of the marketing buzzwords used to describe the effects of skincare merchandise? We reached out to an anti-aging expert and board-certified Denver Plastic Surgeon, Dr. Manish Shah. Shah advocates helping consumers understand what this frequently used language means. Dr. Shah is also an ethical patient safety advocate. 

“There are many ways marketers attempt to pull the wool over the eyes of the consumer with empty phrases and jargon,” comments Dr. Shah. “A phrase such as ‘clinically tested’ and ‘doctor recommended’ is used to mislead consumers into thinking a certain product has more credibility than it actually does.” However, Dr. Shah explains, when these phrases are used it says nothing for the results of the clinical tests or what the products were tested for. In terms of products being “Doctor recommended,” Shah warns that “consumers don’t know what doctor recommended the product in most cases and if those doctors are getting some sort of incentive for endorsement.” 

Dr. Shah shares common marketing jargon phrases used to mislead consumers. 

A Product that claims “Patented Technology” 

“Patents are not necessarily a foolproof sign that something is groundbreaking or effective,” explains Dr. Shah. “Marketers use this language to convey innovation and superiority that their product might not necessarily have over its competitors,” he says. Patents are sometimes authorized through technicality instead of breakthrough meaning any new combination of ingredients, methods or production process can be patented as long as it is new.

“Maximum strength” 

This is a term used often by skin cleansers and moisturizers. “It’s a relative term and the consumer doesn’t really know what it is relevant to. It’s language that entices the shopper to make the purchase without really telling them how it accomplishes ‘maximum strength’ results,” says the Denver Plastic Surgeon.  

“Clinical strength” 

From painkillers to hydrating serums, companies love to bill their products as having “clinical strength.” Dr. Shah says consumers should practice healthy skepticism with such claims. “A product that claims it has clinical strength, in many cases, could have been tested by the doctors developing it. If you think about it you can’t really pinpoint what that phrase means because it is relative and we have no context as to what the company considers clinical strength,” says Shah. The perception, explains Dr. Shah, is that the product is better because the world clinical makes it sound more credible. 

“For All Skin Types” 

“This is a difficult promise to deliver on,” says Shah who has practiced his specialty for 14 years. “Not all skin is the same. If someone has an allergy to an ingredient or some form of dermatitis they really should speak to their doctor about what products are best to include in their regiment instead of blindly trusting a label,” he says. 

“FDA Approved”  

The FDA has different protocols for skincare products that make cosmetic claims as opposed to those that make more medical claims such as promising to increase production of collagen in the skin. Since that is a body function the FDA treats those differently than normal skincare products. However, the FDA just stipulates that the product being sold is safe to use in the manner in which it is directed to be used “FDA approval is not credential that shows the superiority of results,” says Dr. Shah. The plastic surgeon recommends that you not be sold on the sole factor of an FDA approval. 

“Anti-Aging, Revitalizing, or Age Defying”

We’ve all seen these on the labels of some cream or serum or advertised in a commercial where beautiful models and actresses are displayed in all of their airbrushed and well-lit perfection. “These terms are somewhat misleading in that they give the perception of an unrealistic turning back of the clock,” says Dr. Shah. To many consumers viewing an advertisement, it might seem like buy and using that product will help them look like an ageless actress and that is not accurate.” Aging gracefully and maintaining a more youthful look has a lot to do with nutrition, exercise, genes, consistent skin care, stress levels, and cosmetic procedures when necessary. But according to Shah, people cannot cling onto just one aspect in order to look their best and no one product will reverse the clock. 

Medical-Looking Packaging

Be wary of bottles that look like test tubes, labels or packages that include a medical or first aid cross, or feature type that looks like Rx suggesting that it’s a prescription-strength formula even though it’s sold over the counter.

Botanical 

Dr. Shah explains that “An actual botanic is technically an ingredient that is derived from a plant. But, again, “botanical” may be used in advertising to refer to something that is synthetic but acts similar to a plant-based ingredient.”

Instant Results 

Keep in mind that “instant results” aren’t the same as “long-term results.” Meaning, you may use a product that gives you instant moisture or has a quick-acting firming effect, but those results may fade after a few hours and require reapplication. Dr. Shah’s final advice: “Check a product to make sure it specifies whether its “instant” effects are long lasting or short term.”   

Firming

What you think it means: Proven to make skin look tauter.

What it really means: Essentially nothing. “There is no objective way to measure firming,” says Dr. Shah “When a brand says their product has been shown to firm your skin, that claim can only be based on very subjective consumer perception.” 

Natural

 What you think it means- Make from the earth’s own ingredients with no chemicals 

What is really means-  

“Natural” doesn’t necessarily mean anything about the purity of a product. It’s a term that hasn’t been defined by the FDA. To determine what’s actually in a product, read the ingredients list. How many can you pronounce? If they sound like a list of chemicals, they are. There may be a benefit for some people to avoid parabens, usually absent from “natural” products, if their skin is sensitive.

Gluten-Free

What you think it means- That the product is not made with any gluten. 

What it really means- Unlike foods, cosmetics labeled “gluten-free” aren’t regulated by the FDA. Do you need gluten-free beauty products? Maybe, if you’re gluten-sensitive and it’s a lipstick, gloss, or balm, which you could ingest in tiny amounts. Otherwise, it’s not necessary.  

 About the Expert: 

 www.drmanishshah.com

Dr. Manish Shah M.D., F.A.C.S. is board-certified by the American Board of Plastic Surgery and member of the American Society of Plastic Surgeons, the American Society of Aesthetic Plastic Surgery and the International Society of Aesthetic Plastic Surgery. Dr. Shah’s specialties include revision facial aesthetic surgery, rhinoplasty (“nose reshaping”), and aesthetic surgery of the breast (breast augmentation, breast lift, breast reduction). He is, however, well-trained in all areas of aesthetic surgery. Dr. Shah’s aim is to obtain a natural appearing transformation that complements the real you.




Five Simple Isometric Exercises for a Full Body Workout

There are five basic exercises that have been around since humans have been walking on two legs – the squat, lunge, push-up, pull-up and sit-up. But pull-ups and push-ups can be too difficult for many people and all five can cause muscle strains or other injuries if done improperly. We recommend doing these simple isometric exercises with the Activ5 fitness tracker and app so you can exercise safely and effectively, and also monitor your activity and progress.

Isometric Squat

The Activ5 version of the isometric squat is the Chair Pose. Often referred to as the “mother” exercise, a properly done squat works almost your entire body with one exercise.

  • Stand up straight and place Activ5 between both knees (if you don't have the Activ5, simply press your knees together)
  • Extend both arms in front of you.
  • Bend your knees and slowly squat down as if you’re about to sit in a chair, keeping your hips above your ankles. Stop when you’re a few inches above your “chair.”
  • Press Activ5 with your knees as you squeeze your thigh muscles. Your app will tell you how long to hold the pose. Trust us. You’ll feel the burn. (If performing without the Activ5, you can simply keep pressing your knees together for about a minute).

Isometric Lunge

The Activ5 version of the lunge is the Single Leg Deadlift, which is done on both the left and right leg individually. Let’s start with your left foot.

  • Step forward with your left foot.
  • Lower your hips until both knees are bent at about 90 degrees.
  • Place Activ5 on your left leg just above the knee and press Activ5 as you squeeze your leg muscles (If performing without the Activ5, simply place your hands in the same area and position as shown in the picture and press for 60 seconds or longer until you feel the work on your muscles).
  • Keep your left heel firmly on the ground. Again, use your app for guidance. 
  • Repeat with your right leg.

Pull-Up

A pull-up requires a great deal of arm and shoulder strength. Activ5 has over a dozen exercises that work the same muscle groups. We’re using the Hook, which works your biceps, shoulders, and core.  Do this one sitting down. As with the lunge, you do this for both your left and right arms individually. 

  • Make a fist with your left hand.
  • Bend your left elbow and bring it up until your left arm is parallel to the ground.
  • Hold Activ5 in your right hand in front of your left fist.
  • Press Activ5 between your left fist and right palm.
  • Repeat with your right fist and left palm.

Push-Up

As with the pull-up, the push-up requires a variety of muscle groups, including your chest, and Activ5 has several exercises to develop these muscle groups. Let’s start with the Standing Chest Press.

  • Hold Activ5 between both hands in “prayer” position, with your elbows out.
  • Press both palms into Activ5 to squeeze your chest muscles. 
  • Keep both feet firmly on the ground.

Sit-Up

Old fashioned sit-ups often result in back injuries. Activ5 gives you a safer sit-up with the Crunch.

  • Lay on your back with your knees bent, feet flat on the ground and knees about hip-width apart.
  • Place your hands on your chest, with Activ5 beneath your palms.
  • Contract your core to lift your head and shoulders off the ground.
  • Press Activ5 as you squeeze your core muscles.

That’s the Activ5 Full Body Simply Daily Workout. If you don’t have the Activ5, you should know just worked your arms, abs, shoulders, legs and butt. The Activ5 app can show you other exercises that replicate these 5 core exercises.

Stetson University Receives $266,000 NSF Grant for New Microscope

Faculty, students to use the inverted fluorescent microscope in 

biology, health sciences, physics research

DELAND, Florida, Sept. 18, 2019 -- Stetson University has received a $266,000 Major Resource Instrumentation Grant from the National Science Foundation (NSF) to purchase an inverted fluorescent microscope system capable of imaging over a wide range of living biological samples from subcellular structures to small organisms. 

The microscope system will be used at Stetson to engage undergraduate students across biology, health sciences and physics in superior training through faculty-mentored research projects, and promote the implementation of inquiry-based lab experiences for students in upper-level biology and physics courses. 

“This really opens up new avenues of research at the cell and, especially, the sub-cell level at Stetson,” said Holley Lynch, PhD, assistant professor of physics and Stetson’s principal investigator. “We have a growing number of researchers who work with that scale in three departments. And it will allow students to use a research-grade microscope.”

Lynch noted that while some of Stetson’s science faculty/researchers need to see “very small things, such as look inside cells,” others need to see how cells behave over time. The new system, which is expected to arrive on campus later this fall, is “flexible,” she said.

“I see this as a really good stepping-stone. Having this equipment here enables us to apply for other kinds of grants that will fund our research and take our students to the next level,” said Heather Evans-Anderson, PhD, assistant professor health science and a co-principal investigator along with Lynn Kee, PhD, assistant professor of biology; and Roslyn Crowder, PhD, associate professor of biology. 

Highlights of the anticipated research: 1) tracking migrating cells in living tissues to link cellular and subcellular mechanisms to tissue-scale movements; 2) examining improperly located cell death proteins in malignant cells; 3) dissecting communication pathways that regulate cardiac myocyte cell proliferation and regeneration in Ciona intestinalis; 4) examining spatial organization and dynamics of iridescent marine bacteria; and 5) promoting education through use of CRISPR/Cas9 gene editing technology by undergraduates in a Genetics course to manipulate and label genes in order to visualize effects in living organisms. 

Also, the system will provide a substantial foundation to support and enable fundamental pioneering research by junior faculty members, and foster sophisticated capstone research for seniors under the mentorship of faculty members committed to student training and advancing the participation of underrepresented and minority undergraduates in the sciences.

Collectively, these invaluable experiences will promote scientific competency in students as they achieve a comprehensive range of career goals and contribute to the development of the next generation of scientists.

In 2018, Kresge Foundation funds led to Stetson’s acquisition of an advanced stereo microscope, which effectively aids in the visualization of tissue layers and development of organisms. The new microscope system will deliver even greater power of magnification and capability to see inside cells, Evans-Anderson said, adding that extensive interdepartmental collaboration will result.

The NSF, created by the United States Congress in 1950 to “promote the progress of science,” among other initiatives, deemed the Stetson grant’s intellectual merit and broader impacts a reflection of its statutory mission and worthy of funding. The Major Research Instrumentation Grant program accepted 805 funding proposals, requesting more than $557 million, and only 130 to 145 awards were given.

With an annual budget of $8.1 billion, NSF is the funding source for approximately 27 percent of the total federal budget for basic research conducted at U.S. colleges and universities.

About Stetson University

Founded in 1883, Stetson University is the oldest private university in Central Florida. Stetson focuses on intense learning experiences in a supportive community that allows students to develop their voice in a connected, inclusive environment. Stetson University ranks No. 5 on U.S. News & World Report’s 2019 list of Best Regional Universities (South), and has been recognized as one of The Princeton Review’s 385 Best Colleges, 2020 edition. Stay connected with Stetson on social media.

Biosimilars Working Group Responds to Phase II of the BC PharmaCare Biosimilars Initiative

VANCOUVER, Sept. 18, 2019 /CNW/ - On September 5, 2019, the BC government announced phase two of its Biosimilars Initiative, informing patients prescribed the originator biologic drug, Remicade® (infliximab), to treat inflammatory bowel disease (Crohn's disease and ulcerative colitis) that this medication will no longer be covered by the province, and that they must switch to a biosimilar infliximab, either Inflectra® or Renflexis®.1 This means that patients have only six months to meet with their gastroenterologist to discuss switching their medication and to start a replacement product. The sweeping change in coverage is driven by the government's decision to generate significant healthcare savings from switching patients' medication rather than negotiating with the makers of the originator biologic to lower their prices. 

Biologics are medicines created from living cells and are used to treat a variety of conditions, such as Crohn's disease, ulcerative colitis, diabetes, rheumatoid arthritis, cancer, osteoporosis, psoriasis, HIV, multiple sclerosis, and growth deficiencies, to name a few. Biosimilars are highly similar to an originator biologic, but different enough to be sold under their own brand name. Because these drugs are made from living cells, it is impossible to create an identical copy regardless of the use of the exact same manufacturing conditions, ingredients, and process.2 This is a stark comparison to generic drugs, which are made up of chemicals that can be reproduced with the same active ingredient as the original brand name product.3

Health Canada considers a biosimilar to be safe, effective, and of good quality, and highly similar to the originator biologic it references. For a number of reasons, including that the biosimilar companies do not have to invest in discovery and clinical trials, these medicines provide lower-cost options for public payers. However, as the originator biologics are now off-patent, the companies that own these products are willing to negotiate lower prices. Unfortunately, public drug plans prefer to support a biosimilar market. 

It is important to note that biosimilars, unlike generic medications, are not interchangeable with the innovator biologic medication. Health Canada set the bar, saying, "Biosimilars are not generic biologics and many characteristics associated with the authorization process and marketed use for generic pharmaceutical drugs do not apply. Authorization of a biosimilar is not a declaration of pharmaceutical equivalence, bioequivalence or clinical equivalence to the reference biologic drug." Be wary of anyone who calls biosimilars "biogeneric", as this is an unacceptable, made-up word for these products.

Health Canada further states that the treating physician, in consultation with the patient, should make the decision to switch a patient after taking into account available clinical evidence.

Canada is the only country in the world to have comprehensive patient support programs paid for by the pharmaceutical companies. This means patients receiving intravenous infusions will need to switch to another group and location to receive their treatment, which could add further stress as they adjust to a new location of care and a new support staff.

The change in coverage is estimated to affect 1,700 patients. This is in addition to about 20,400 British Columbians diagnosed with ankylosing spondylitis, diabetes, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis affected from phase one of the Biosimilars Initiative. This population includes pediatric patients, while pregnant patients may be provided exceptional coverage following approval of request from PharmaCare's Special Authority branch.4

The Biosimilars Working Group, a diverse cohort of health patient groups dedicated to ensuring the best outcomes for patients, welcomes the BC government's expansion for access to healthcare services, such as full coverage for the fecal calprotectin test and increased funding for nursing support. However, the cost-driven objective of the forced-switch policy is worrisome as it fails to put physician wisdom, patient choice, appropriateness of care, accessibility, and affordability at the forefront of health policy. Patients should only switch if they decide that this is the best course of action for their conditions, with consultation from their treating physician.

Gail Attara, President & CEO of the Gastrointestinal Society, and member of the Biosimilars Working Group, shared that, "Every disease area is unique and each needs to be treated differently. Patients with limited therapeutic options should not be lumped together with those who have a broader range of options available to them. Many people depend on public coverage and only a select few have private health plans that do better."5

Surveys conducted on various healthcare stakeholders, including patients, physicians, family caregivers, and the public, in Canada and abroad, reveal synonymous conclusions that treatment decisions should remain between a patient and their physician. Health Canada also encourages patients to speak with their treating physician about switching.6

In 2017, five patient organizations collaborated on a project that surveyed Canadian patients with inflammatory diseases about their perspectives on biologics and biosimilars. Of the 657 individuals surveyed, a vast majority reported being opposed to a forced switch for non-medical reasons. 

"We are deeply concerned about the risks associated with a switch. Already, patients with loss of vision depend on accessibility and informed consent when being administered treatments. Furthermore, patients who are stable on a biologic treatment should not be made to potentially jeopardize their safety and quality of life with a mandated switch," said Louise Gillis, National President of the Canadian Council of the Blind.

Biosimilars in oncology are expected to increase in the Canadian market and the implementations made by the BC government concern many cancer patients. "While we are aware of the value of biosimilars, the Canadian Cancer Survivor Network believes that patients who are being successfully treated by biologics should not be forced to switch. Any such decisions should be made by patients in consultation with their clinicians," shared Jackie Manthorne, President & CEO of the Canadian Cancer Survivor Network.

The BC Ministry of Health precipitates the need to increase biosimilar uptake due to best practices in the European market, having had over a decade of experience with these products. The Alliance for Safe Biologic Medicines (ASBM), an international and multi-stakeholder organization comprised of healthcare groups, patients, physicians, and biotechnology companies, responded to the BC announcement by releasing a fact sheet analyzing the claims purported by the provincial government."European countries, for example, enjoy robust biosimilar markets and higher uptake rates, yet the vast majority leave the decision on what biologic medicine to use with the treating physician, in consultation with their patient. No country in Europe has ceased the reimbursement of originator biologics by a government decree such as that issued in BC and only very few countries use a procurement process that will reimburse a single product that wins the bid," said Michael Reilly, Executive Director of ASBM.8

The Biosimilars Working Group will continue to raise the importance of patient choice and evidence-based decision making with policymakers. To lean more about this group and to stay up-to-date with biosimilars research and policies, please visit www.biosimilaroptions.ca and follow @BiosimilarsWG on Twitter.

Working Group Members Participating in This Media Release:
Alliance for Safe Biologic Medicines
Canadian Cancer Survivor Network
Canadian Council of the Blind
Canadian Society of Intestinal Research
Gastrointestinal Society

_______________________
1 Biosimilars Initiative for Patients. Province of British Columbia page. Available at: https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/biosimilars-initiative-patients. Accessed 2019-09-11.
2 Biologics and Biosimilars. GI Society page. Available at: https://badgut.org/information-centre/a-z-digestive-topics/biosimilars-pamphlet/. Accessed 2019-09-11. 
3 Biosimilar biologic drugs in Canada: Fact Sheet. Government of Canada page. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html#a17. Accessed 2019-09-11.
4 Biosimilars Initiative for Patients. Province of British Columbia page. Available at: https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/biosimilars-initiative-patients. Accessed 2019-09-11.
5 Gail Attara, "Balancing Act: Cost Containment vs. Patient Health Outcomes," GI Society Canadian Society of Intestinal Research, available at https://badgut.org/balancing-act/, Accessed 2019-09-11.
6 Biosimilar biologic drugs in Canada: Fact Sheet. Government of Canada page. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html#a17 Accessed 2019-09-11.
7 ASBM Releases Fact Sheet on British Columbia vs EU Substitution Policies. Alliance for Safe Biologic Medicines page. Available at: https://safebiologics.org/wp-content/uploads/2019/08/ASBM-Factsheet-BC-vs-EU-Substitution.pdf. Accessed 2019-09-11.
8 ASBM Raises Concerns for Patients as BC Gov't Expands Biologics Forced-Switch Policy. Alliance for Safe Biologics page. Available at: https://safebiologics.org/2019/09/asbm-raises-concerns-for-patients-as-bc-govt-expands-biologics-forced-switching-policy/. Accessed 2019-09-12.

SOURCE Biosimilars Working Group

5 Principles of Martial Arts to Incorporate in Your Exercise Routine

(credit: Photo by Thao Le Hoang on Unsplash).


By now, virtually everyone knows the importance of living an active lifestyle. Working out helps boost your fitness levels and decreases the risk of certain diseases. Incorporating the principles of martial arts into your exercise routine can have a very positive impact. Here are five principles to remember.

Display Discipline

Maintaining a disciplined mindset is one of the biggest principles of Shaolin martial arts. As you may have experienced, motivation often comes and goes. There will be times when you simply don’t want to work out. However, disciplined people fight the temptation to take days off. They recognize the value of sticking to their regimen.

Don’t Give Up

The process of becoming fit isn’t always easy. When results don’t happen fast enough, it’s not uncommon for a person to give up. The principles of martial arts teach you to keep pushing past obstacles. Warriors never allow setbacks to stand in their way. Always keep your goals in sight. If you need a little extra inspiration, wear a Jiu-jitsu t-shirt.

Take Care of Your Body

Martial artists must stay prepared for battle. Nurturing their body is especially critical. Try to implement this same principle in your life. By taking care of your basic health, you will have greater stamina. The extra energy will help you to exercise more efficiently. Strive to eat nutritious meals on an everyday basis. If you are dealing with an injury, give your body enough time to heal. Getting a good night’s sleep is just as essential.

Put Forth Great Effort

To be a great martial artist, one must put forth a valiant effort. During your exercise routine, remember the importance of putting your best foot forward. Working hard is bound to pay off in the long run. Even if you’re in a bad mood, never make the mistake of developing a lazy attitude.

Mind Over Matter

Martial arts involves more than just kicking and punching. In fact, a person’s mind is actually their most powerful weapon. While exercising, try to maintain a clear and focused mind. Don’t allow any personal issues to ruin your workout. Concentrate solely on your fitness regime. Small things, like keeping a good posture and breathing effectively, can make a big difference.

The principles of martial arts can take your exercise routine to the next level. Develop the psyche of a true champion. A few changes will help you to achieve great success.

Scotiabank supports young Canadians with a $500,000 donation to the Terry Fox PROFYLE program

TORONTO, Sept. 18, 2019 /CNW/ - Scotiabank has donated $500,000 to the Terry Fox Foundation PROFYLE program, to help give young Canadians with hard-to-treat cancers access to potentially life-saving treatment. 

The Terry Fox PROFYLE – short for PRecision Oncology For Young peopLE – is a unique program that uses precision medicine to treat qualifying babies, children and young adults across Canada. Through this project, patients who are out of treatment options have their tumours and genomes profiled and analyzed, and are connected to a network of top cancer researchers. This helps to identify drugs that might work for these patients based on the molecular profile of their tumours.

"Young people are our future leaders and Scotiabank's goal is to help ensure that they have the necessary resources they need to support their success," says Karen Soos, Director of Philanthropy at Scotiabank.  "We are investing in Terry Fox PROFYLE to help young people thrive and reach their infinite potential through improved access to the best healthcare. This program gives another chance to young people who have been told there are no more treatment options."

Scotiabank and its employees are focused on enriching the lives of young people in the community. Through this donation, Scotiabank hopes to give more young people resources to help them grow into healthy, contributing adults. The Terry Fox PROFYLE program began in 2017 and today more than 300 children enrolled.  

"We are so grateful for the support and commitment of Scotiabank in helping us to find new treatments and more answers for the 20% of children, adolescents, and young adults with hard-to-treat cancers," says Heather Scott, Director of Development at The Terry Fox Foundation. "Terry Fox PROFYLE is an unprecedented Pan-Canadian precision medicine project that is showing promising results towards this goal. This initiative is possible thanks to the generosity of our donors like Scotiabank."

Scotiabank has had a long relationship with the Terry Fox Foundation, dating back to Terry's Marathon of Hope in 1980. Donations for the Terry Fox Run can be made at Scotiabank branches across Canada. 

About Scotiabank

At Scotiabank, we aim to support organizations that are committed to helping young people reach their infinite potential. Young people are our future leaders and Scotiabank's goal is to help ensure that they have the necessary skills and resources they need to support their success. Together with our employees, the Bank supports causes at a grassroots level. Recognized as a leader for our charitable donations and philanthropic activities, in 2018, Scotiabank contributed more than $80 million to help our communities around the world.

Scotiabank is Canada's international bank and a leading financial services provider in the Americas. We are dedicated to helping our more than 25 million customers become better off through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With a team of more than 100,000 employees and assets of over $1 trillion (as at July 31, 2019), Scotiabank trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit www.scotiabank.com and follow us on Twitter @ScotiabankViews.

SOURCE Scotiabank

Spin Before You Spend: Our Favorite Free Online Spin Classes & Workout Videos

Free online spin class

 
Still on the fence about Spinning? This is your lucky day, because we’ve collected 6 free Spin classes that might change your mind.

But a word of caution: Not All Spin Classes Are Created Equal!

  1. Ultimate Cardio Zone Ride: 25 Minutes
PNG image

Nothing else can get you to those fat-burning heart rate zones like Spin. And with this 28-minute ride, our fearless leader Cat Kom will absolutely put your heart through the ringer and back. Get ready, because you’re headed to the cardio zone.

  1. Pedal with Power: 20 Minutes
A picture containing person, indoor, road, wall

Description automatically generated

Are you a beginner Spinner or a cycling savant? No matter your skill level, this power-focused cycling workout just needs 20 minutes to get your heart absolutely pumping.

  1. Workout for Beginners and Experienced Riders: 60 Minutes
A group of people standing in a room

Description automatically generated

How long can you go? If you’re ready to go the distance, check out this amazing charity ride cycling class that goes on for a full hour.

  1. Calorie-Crusher: 30 Minutes
A group of people standing in front of a crowd

Description automatically generated

This free Spinning class is quick, but it ain’t easy. In just a half-hour, Cat will guide you through smooth jumps, fat-burning sprints, and climbs that’ll leave you shaking at the knees. But trust us—you’re going to feel amazing after this one.

  1. Road Rider Rush: 15 Minutes
A picture containing indoor, man, person, wall

Description automatically generated

Looking to just break a quick sweat road riding style? This is the express ride for you!

  1. Prime Climb : 45 Minutes

PNG image

Defy gravity with this intense climb that’ll push your quads to the absolute limit. Think you can take it? This class goes an incredible 45 minutes, meaning you’ll absolutely work your cardio and sculpt your legs.

Avicanna (TSX: AVCN) Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS./

TORONTO, Sept. 13, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it will further the research and development and pre-clinical analysis of its proprietary prescription and over-the-counter ("OTC") cannabinoid products and formulations through an exclusive research agreement with the University of Guelph in Canada for a project to be performed by Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, Ontario Veterinary College, Department of Biomedical Sciences, as principal investigator.

"We believe the studies that we have designed with Dr. Khokhar, which will be performed by his team at the University of Guelph, will provide a unique opportunity to evaluate disorders of brain health and are an essential step in a committed research program for evaluating the role of cannabinoids as therapies for several human neurological disorders," said Dr. Amza Ali, the Company's Chief Medical Officer.

The collaboration with the University of Guelph will focus on evaluating a variety of dosage forms on preclinical models of several human psychiatric conditions, including depression, anxiety, schizophrenia, PTSD and substance abuse. A unique aspect of this collaboration is to determine brain cannabinoid levels and cerebral activity function using electrophysiology and behavioral methods with various Avicanna formulations and common to rare cannabinoids.

Additional studies include research in the treatment of nicotine and alcohol addiction with the use of various cannabinoid formulations provided by Avicanna. Analysis of vaporizer formulations amongst others will be tested on preclinical models of neuropsychiatric disorders to potentially reduce/replace doses of THC with CBD.

"Avicanna is focused on elevating the scientific research related to cannabinoid products through its collaborations with world-class research institutions in order to provide patients and physicians with products that offer a well understood mechanism of action, efficacy, and safety profile. We are excited to advance our research and development program for psychiatric disorders and substance dependency, building on our data and expertise within the cannabinoid market," stated Aras Azadian, Chief Executive Officer.

The services to be performed under the research agreement will be provided on an exclusive basis and Dr. Khokhar's laboratory has agreed to not conduct testing on any formulations or products similar to the Company's products during the term of the agreement. All research data and research reports created under the research agreement will remain the sole property of Avicanna, however, Avicanna has granted a license to the University of Guelph to use such reports and data for research and academic purposes. The studies under this agreement are expected to take two (2) years and the cost of the studies are expected to be approximately $300,000.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements

Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the intended outcomes of the studies to be conducted under the research agreement, the disorders to be studied and the expected term and cost of the studies. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.

SOURCE Avicanna Inc.

Japanese Goku Spa Offers Innovative Techniques To Help Americans Finally Get To Sleep 

More than a third of American adults are not getting enough sleep on a regular basis, according to a study in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.  Atsumi Kaneda, founder of US based Goku Spa (www.gokusleep.com) hopes to help reverse this trend. "We refer to Goku as the "ultimate sleep" spa because we exclusively focus on the scalp." said Atsumi Kaneda. "Our techniques are designed to put in an individual in the most relaxed state possible to ensure they drift off into a peaceful slumber."  Kaneda founded Goku in 2008 in Japan after suffering from years of insomnia. Kaneda was constantly exhausted during the day as a result of poor quality sleep. Seeing that self-care in Japan was a growing trend, Kaneda sought to solve her own problem as well as bring that solution to others. "Since there were no market for head massage, there were no books nor school for it. I had to invent it myself." Said Kaneda. "I studied under various doctors, acupuncturists, and healers to gain knowledge and techniques about what induces maximum relaxation and puts the body in the optimal state for sleep ." Kaneda created her special form of treatment called Zecchou Sleep (meaning "ultimate sleep"), which is done without water or oil. The technique is composed of twenty-one types of strokes. Pressure and direction using the fingers are applied to the scalp, facia, and muscles of the head. The therapists hands move slowly to lose the move the muscles of the head which result in more blood flow and circulation. Beneath the scalp are the large fascia and some thin muscles. "The pressure slowly stimulates the parasympathetic nerves system, and leads the clients to wonderful sleep. This sleep is different from meditation or nighttime sleep, it is a new experience of a pleasurable dreamy land." said Kaneda. "In addition the treatment, each Goku spa has visually soothing lights and music which can enhance the experience."  Goku's four locations in Japan have become so popular, that there are currently 498,721 people on the waiting list for appointments. In 2019, Kaneda opened her first Goku spa in the US rightfully so in New York which is known as "the city that never sleeps."  "Our mission is to alleviate sleep difficulties and discomfort. We want to make insomniacs sleep. We want you to experience joyful and pleasurable sleep, and make your dreams more colorful. If Goku’s treatment and experiences can bring joy and relieve any pain you have during sleep, that is my greatest pleasure." said Kaneda. For more information about Goku spa, please call (929) 336-3088 and visit: https://www.gokusleep.com/   For all interviews please call Ryan McCormick of Goldman McCormick Public Relations (www.goldmanmccormick.com) at 516-901-1103 / 919-377-1200

Santé Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Québec Healthcare Professionals

MONTREAL and SMITHS FALLS, ON, Sept. 16, 2019 /CNW/ - Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients.

Santé Cannabis, a pioneer in medical cannabis in Québec, has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics. 

"Patient referrals and training requests from our physician colleagues have increased by more than 500 per cent over the last year," says Dr. Michael Dworkind, Medical Director of Santé Cannabis and McGill University Associate Professor of Family Medicine. "It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool. In this program, we extend our experience and expertise to healthcare professionals, in order to support them to meet the needs of their patients."

The Prescriber Training Program is designed by clinicians for clinicians, and gives a unique, practical approach to medical cannabis learning. It provides participating physicians with:

  • Self-learning modules that detail treatment evidence for specific conditions and symptoms; 
  • Ongoing personalized phone support for questions about medical cannabis and patient care; 
  • Clinical preceptorship opportunities at four Santé Cannabis locations across Québec; 
  • Practical reference guidebook on developing and managing treatment plans and dosing; and 
  • Clinical toolkits to help navigate patient assessment and follow-ups.

"A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum," comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We've invested in a range of training and education initiatives to address this gap in knowledge, and this new program creates an important resource for Québec physicians interested in learning how to integrate medical cannabis into their practice."

As Québec's first and foremost medical cannabis clinic and research centre, Santé Cannabis has received referrals from more than 2,500 physicians and assessed over 6,000 patients since 2014, while also providing information sessions for patients and healthcare professionals. Spectrum Therapeutics' track record with providing industry-leading education, resources and support for healthcare professionals includes:

  • Evidence-based educational courses in Canada that have been delivered to thousands of physicians, nurses, and pharmacists, including accredited medical education programs through the Canadian Council on Continuing Education in Pharmacy (CCCEP) 
  • A first-of-its-kind Catalyst Peer Mentorship Program, which links physicians from across Canada with colleagues who possess advanced knowledge of the cannabis field in order to provide case-by-case support. 
  • 71,000+ interactions with healthcare professionals

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. Santé Cannabis Medical Director Dr. Michael Dworkind, Practicing Physician Dr. Alain Watier, and Canopy Growth Chief Medical Officer, Dr. Mark Ware will be available for interviews. Event details below:

Date: Tuesday, September 17th 2019
Time: 9:00AM to 5:00PM
Address: 225-4150 Rue Sainte-Catherine Ouest, Westmount, H3Z 2Y5
RSVP: If you'd like to attend, please RSVP with Lilia Rassoul (media@santecannabis.ca)

ABOUT SANTÉ CANNABIS
Santé Cannabis is Québec's leading specialized medical cannabis clinic and research centre, with clinics operating in Montreal, Quebec City, Sherbrooke and Pointe Claire.  Santé Cannabis is a trusted and essential consultative service for over 2500 physicians who have referred more than 12,000 patients since 2014. The clinical care team is comprised of family physicians and specialists in chronic pain, cancer, gastroenterology, and endocrinology, as well as nurses with clinical expertise in cannabis medicine.  Santé Cannabis provides online and onsite training for healthcare professionals, researchers, and decision makers from all over the world. As a Contract Research Organization specialized in medical cannabis, Santé Cannabis offers consultation, data management and clinical trial services to a diverse range of clients from pharmaceutical, biotech and cannabis industries.

ABOUT SPECTRUM THERAPEUTICS
Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED, NYSE: CGC), is dedicated to educating healthcare practitioners, furthering the public's understanding of medical cannabis and its various applications, and cutting edge, commercializable research and IP development. Founded in Canada, Spectrum Therapeutics operates in Australia, South America, Africa and across Europe. Its products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded spectrum to categorize medical cannabis according to THC and CBD levels. 

Spectrum Therapeutics' offerings include whole flower cannabis, oils and new innovations such as Softgels in addition to single cannabinoid medicine Dronabinol under the brand Bionorica Ethics. Through product simplification, robust clinical research and ongoing education of healthcare professionals, Spectrum Therapeutics is committed to addressing the unmet medical needs of patients around the globe.

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents. The Company's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics. The Company operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include "most up-to-date clinical guidelines, support networks, online and in-person training opportunities", and "will be offered for free". Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including medical cannabis regulations and such risks contained in the Company's annual information form dated June 24, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

SOURCE Canopy Growth Corporation